Concord Biotech Limited CONCORDBIO NIFTY_SMALLNSEPHARMA
Company Overview
Concord Biotech Limited, a, biopharma company, engages in the research and development, manufacture, and sale of pharmaceutical products in India and internationally. It operates through Active Pharmaceutical Ingredients (APIs) and Formulations segments. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin, doxorubicin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment. In addition, the company provides mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, daptomycin, fusidic acid, colistimethate sodium, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi acetate, micafungin sodium, and nystatin for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. Further, the company provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.
Why Investors Should Care
Return on capital employed stands at 16.7%.
Maintains a net profit margin of 24.9%.
Carries low leverage with a debt-to-equity ratio of 0.11.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Mar 2026 Revenue of ₹1,046.36 Cr (-11.3% YoY); net profit ₹260.91 Cr.
- Trailing 12 Months Year-on-year growth — revenue -11.3%, earnings -29.8%.
- 5-Year Trend Long-term compounding — revenue CAGR 8.0%, profit CAGR 2.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 8.00% |
| 1 Year: | -11.31% |
Compounded Profit Growth
| 5 Years: | 2.81% |
| 1 Year: | -29.80% |
Stock Price Performance
| 1 Year: | -12.96% |
| 6 Months: | +18.09% |
| 3 Months: | +12.06% |
| 1 Month: | +3.08% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)44.59 · Neutral
P/E of 57.19 is above the sector median of 41.64 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Excellent profit margin of 24.9%.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading at a high P/E of 57.2.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CONCORDBIO Concord Biotech Limited NIFTY_SMALLNSEPHARMA | 1,417.10 | 57.19 | ₹14,825.16 Cr | 0.55% | 16.70% | 12.93% | 8.00% | 2.81% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,899.00 | 39.73 | ₹4.56 L Cr | 0.82% | 17.94% | 13.74% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 9,100.00 | 94.06 | ₹2.42 L Cr | 0.36% | 18.96% | 15.32% | 10.98% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,857.00 | 75.99 | ₹1.64 L Cr | 0.77% | 9.05% | 25.79% | 13.27% | 20.22% |
| 5 | APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA | 8,650.00 | 64.10 | ₹1.24 L Cr | 0.22% | 19.20% | 20.48% | 14.85% | 33.34% |
| 6 | LENSKART LENSKART SOLUTIONS LTD NIFTY_MIDNSEPHARMA | 684.90 | 236.17 | ₹1.19 L Cr | 0.00% | 7.21% | 5.65% | 35.38% | 66.99% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,120.00 | 22.36 | ₹1.13 L Cr | 0.09% | 19.04% | 18.59% | 16.55% | 36.99% |
| 8 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,385.00 | 28.85 | ₹1.12 L Cr | 0.88% | 14.86% | 11.27% | 7.23% | 11.45% |
| 9 | LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA | 1,840.00 | 111.85 | ₹99,333.61 Cr | 0.13% | 19.53% | 16.77% | 3.77% | 4.00% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 273.00 Cr | 195.00 Cr | 262.00 Cr | 241.00 Cr | 319.00 Cr | 216.00 Cr | 310.00 Cr | - | - | 203.99 Cr | 247.06 Cr | 277.77 Cr | 326.08 Cr | 257.49 Cr |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | 45.11 Cr | 49.02 Cr | 65.73 Cr | 85.81 Cr | 54.29 Cr |
| Gross Profit | - | - | - | - | - | - | - | - | - | 158.88 Cr | 198.04 Cr | 212.03 Cr | 240.26 Cr | 203.20 Cr |
| Operating Expenses | 146.00 Cr | 123.00 Cr | 147.00 Cr | 135.00 Cr | 187.00 Cr | 135.00 Cr | 176.00 Cr | - | - | 115.26 Cr | 127.94 Cr | 131.80 Cr | 141.28 Cr | 138.92 Cr |
| Operating Income | 113.00 Cr | 59.00 Cr | 103.00 Cr | 92.00 Cr | 118.00 Cr | 68.00 Cr | 121.00 Cr | - | - | 43.62 Cr | 70.10 Cr | 80.23 Cr | 98.99 Cr | 64.28 Cr |
| EBITDA | 127.00 Cr | 72.00 Cr | 116.00 Cr | 106.00 Cr | 132.00 Cr | 81.00 Cr | 134.00 Cr | - | - | 76.57 Cr | 104.13 Cr | 104.98 Cr | 133.70 Cr | 96.48 Cr |
| Interest Expense | 1.00 Cr | 1.00 Cr | 1.00 Cr | 0 | 0 | 0 | 0 | - | - | 5.86 L | 5.91 L | 8.15 L | 8.40 L | 3.64 L |
| Pretax Income | 124.00 Cr | 71.00 Cr | 110.00 Cr | 103.00 Cr | 129.00 Cr | 80.00 Cr | 130.00 Cr | - | - | 58.73 Cr | 85.68 Cr | 86.16 Cr | 114.08 Cr | 78.34 Cr |
| Tax Provision | 32.24 Cr | 16.33 Cr | 28.60 Cr | 25.75 Cr | 33.54 Cr | 20.00 Cr | 35.10 Cr | - | - | 14.67 Cr | 22.62 Cr | 22.51 Cr | 25.61 Cr | 20.65 Cr |
| Net Income | 91.00 Cr | 54.00 Cr | 81.00 Cr | 78.00 Cr | 95.00 Cr | 60.00 Cr | 96.00 Cr | - | - | 44.06 Cr | 63.06 Cr | 63.64 Cr | 88.79 Cr | 57.70 Cr |
| Diluted EPS | 8.75 | 5.21 | 7.74 | 7.41 | 9.08 | 5.70 | 9.15 | - | - | 4.21 | 6.03 | 6.08 | 8.46 | 8.46 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Revenue | 512.00 Cr | 616.00 Cr | - | 830.63 Cr | 998.06 Cr | 1,179.82 Cr | 1,046.36 Cr |
| Cost of Revenue | - | - | - | 197.07 Cr | 241.61 Cr | 317.71 Cr | 259.99 Cr |
| Gross Profit | - | - | - | 633.57 Cr | 756.45 Cr | 862.11 Cr | 786.37 Cr |
| Operating Expenses | 308.00 Cr | 289.00 Cr | - | 328.82 Cr | 370.16 Cr | 398.77 Cr | 481.54 Cr |
| Operating Income | 184.00 Cr | 299.00 Cr | - | 304.75 Cr | 386.28 Cr | 463.35 Cr | 304.84 Cr |
| EBITDA | 205.00 Cr | 327.00 Cr | - | 380.56 Cr | 468.71 Cr | 549.46 Cr | 419.39 Cr |
| Interest Expense | 1.00 Cr | 1.00 Cr | - | 4.51 Cr | 2.55 Cr | 52.93 L | 28.20 L |
| Pretax Income | 214.00 Cr | 313.00 Cr | - | 322.01 Cr | 412.56 Cr | 494.55 Cr | 344.65 Cr |
| Tax Provision | 44.94 Cr | 78.25 Cr | - | 81.93 Cr | 104.46 Cr | 122.91 Cr | 85.42 Cr |
| Net Income | 169.00 Cr | 235.00 Cr | - | 240.09 Cr | 308.10 Cr | 371.64 Cr | 260.91 Cr |
| Diluted EPS | 177.81 | 247.44 | - | 22.95 | 29.45 | 35.52 | 24.78 |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Total Assets | 941.00 Cr | 1,183.00 Cr | - | 1,513.98 Cr | 1,700.71 Cr | 2,034.25 Cr | 2,234.73 Cr |
| Current Assets | - | - | - | 727.70 Cr | 896.23 Cr | 1,135.24 Cr | 1,250.11 Cr |
| Cash & Equivalents | - | - | - | 3.50 Cr | 15.14 Cr | 90.45 L | 12.19 Cr |
| Inventory | - | - | - | 212.31 Cr | 207.95 Cr | 239.67 Cr | 326.36 Cr |
| Receivables | - | - | - | 273.76 Cr | 349.61 Cr | 521.65 Cr | 460.20 Cr |
| Total Liabilities | - | - | - | 223.98 Cr | 174.06 Cr | 221.53 Cr | 219.59 Cr |
| Current Liabilities | - | - | - | 191.84 Cr | 142.16 Cr | 184.06 Cr | 169.08 Cr |
| Long Term Debt | - | - | 31.25 Cr | 6.24 Cr | 0 | 0 | - |
| Total Debt | 52.00 Cr | 86.00 Cr | - | 31.55 Cr | 9.74 Cr | 2.97 Cr | 2.32 Cr |
| Total Equity | 771.00 Cr | 1,000.00 Cr | - | 1,290.00 Cr | 1,526.65 Cr | 1,812.72 Cr | 2,017.06 Cr |
| Shares Outstanding | - | - | - | 10.46 Cr | 10.46 Cr | 10.46 Cr | 10.46 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 155.00 Cr | 167.00 Cr | - | 246.00 Cr | 265.47 Cr | 244.52 Cr | 266.88 Cr |
| Investing Cash Flow | -114.00 Cr | -195.00 Cr | - | -157.95 Cr | -154.61 Cr | -159.99 Cr | -142.72 Cr |
| Financing Cash Flow | -43.00 Cr | 31.00 Cr | - | -85.22 Cr | -99.21 Cr | -98.77 Cr | -112.88 Cr |
| Capital Expenditure | -156.00 Cr | -205.00 Cr | - | -145.08 Cr | -85.69 Cr | -111.17 Cr | -95.15 Cr |
| Free Cash Flow | -1.00 Cr | -38.00 Cr | - | 100.92 Cr | 179.78 Cr | 133.34 Cr | 171.73 Cr |
| Net Change in Cash | -1.00 Cr | 3.00 Cr | - | 2.83 Cr | 11.64 Cr | -14.24 Cr | 11.28 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | 76.3% | 75.8% | 73.1% | 75.2% |
| Operating Margin % | 35.9% | 48.5% | - | 36.7% | 38.7% | 39.3% | 29.1% |
| Net Margin % | 33.0% | 38.1% | - | 28.9% | 30.9% | 31.5% | 24.9% |
| ROE % | 21.9% | 23.5% | - | 18.6% | 20.2% | 20.5% | 12.9% |
| ROCE % | - | - | - | 23.0% | 24.8% | 25.0% | 14.8% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CONCORDBIO
Concord Biotech Ltd Dividend History, Yield & Record Date - INDmoney
<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTE1icS10am1uYTZFaUFPeUtaVzRDZVNQNmNnYTBIdW5JTnZ3VzQtbVRaZDVkWGZObGpjdXVwOXNSRzhObFF6dVd4WjJPZWpKOGJhUVFCdW9udFdPdHNkbkx6amVfTEJqTnQxell4SWNmLU8xdU9KbFByVw?oc=5" target="_blank">Conco…
CONCORDBIO Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMifkFVX3lxTE9ZQ0JfTEJva1U4aFl3c201MVozWjMtNUlJb0o4TndXbjJKWVRBUVJUSWc1Wm5KVEt1Rmp4QVNqTmMyTTB0RHJzLXExNFVweHAzWlRWbHRUZ2Z4bjZhM2Rvc0pXOGxfYkkxRDZEb3ZWYmlqZnZhSjZuUFQtSkxLUQ?oc=5" target="_blan…
Time To Worry? Analysts Just Downgraded Their Concord Biotech Limited (NSE:CONCORDBIO) Outlook - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi8AFBVV95cUxNYVRmWVlKeXFLaUJMai1EcDZSa0hfb2dfMGx1T2d3VzVMN1hzTl9rSkVUbFZWT2lmRi12dEV4ZEVlTUpQRHloRkZRaFl2ZF9vdzl6dFlSLUZ3cng0dVlyOENwc3NWQTN5Zm1EWFJNOWdzVExZbjNIbmR5dXlwVkFNaVFXQUpUenR4SDdra2…
Concord Biotech Hits ₹1,539 Target; Gains 11.4% in 7 Sessions - HDFC Sky
<a href="https://news.google.com/rss/articles/CBMidEFVX3lxTE1UWnpPa0ZjS2FHa3ZZekJyeWFNUnFRT3ppbTgyMDhpd3NaS1hYZnkwMktuS1ljRl9qOGhjZDNiMF9JTXJvdW1LUGFQdGR1SEF0U3EyN01sc1M1Q1IzYlJNUUJRNkdGQVNBTGR3Q0tNVFkxblRK?oc=5" target="_blank">Concord Bio…
Concord Biotech (CONCORDBIO.NS) Edges Lower as Stock Holds Near Key Support - Total Put Call - vinanet.vn
<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxNQlAtQmNMRlU5dmI3N0ZQMGJVNzRZWUhwaWJOcG1CNzdiU2Q4ZVNzZDF5OXZKeHlnREZCTW1fYWpoMGJ5bUZKTlozTzVaVHBxb3k5TjRnM2dfbHlVTE1OeWpIVnlHejZDa1RTLXJySzAxZHNocG91VjY5cmhTNEhOajJEVTRWSlB0a1h2UU…
Concord Biotech Ltd. Share Price Rises on Strong Session - Univest
<a href="https://news.google.com/rss/articles/CBMiggFBVV95cUxQS1hkU3d1alZydXBINFcyUnFEWFQwODJRSzRJdTJRTG80QUhQUTFoS0V5QXBFQWl2aDNQYnFHc0g1YV9WX1BEc1JwUE12WW1yMkgtSF9wYWg2R3dGOWFUYzB0VmdGcE5sY1M3Xy1RZGMtUWp5U1hJY0JOX2I5Qlp4aGRB?oc=5" target=…
CONCORDBIO — Frequently Asked Questions
What is the current share price of Concord Biotech Limited (CONCORDBIO)?
As of 2026-09-08 04:53 IST, Concord Biotech Limited (CONCORDBIO) trades at ₹1,417.10 on NSE. Its 52-week range is ₹1,008.76 to ₹1,745.95.
What is the market capitalisation of CONCORDBIO?
Concord Biotech Limited (CONCORDBIO) has a market capitalisation of ₹14,825.16 Cr on NSE.
What is the P/E ratio of CONCORDBIO?
CONCORDBIO trades at a trailing price-to-earnings (P/E) ratio of 57.19. The industry average P/E is 41.64. Its price-to-book (P/B) ratio is 7.08.
Does CONCORDBIO pay a dividend?
Concord Biotech Limited (CONCORDBIO) currently offers a dividend yield of 0.55%.
What is the return on equity (ROE) of CONCORDBIO?
CONCORDBIO has a return on equity (ROE) of 12.93%. Its return on capital employed (ROCE) is 16.70%.
Is CONCORDBIO a good stock to buy?
This page provides a data-driven analysis of Concord Biotech Limited (CONCORDBIO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.